Terms: = Leukemia AND DDIT3, CHOP, 1649, ENSG00000175197, _C/EBP zeta_, MGC4154, GADD153, CHOP10, P35638 AND Clinical Outcome
9 results:
1. KIR2DS1-HLA-C status as a predictive marker for benefit from rituximab: a post-hoc analysis of the RICOVER-60 and CLL8 trials.
Kaddu-Mulindwa D; Altmann B; Robrecht S; Ziepert M; Regitz E; Tausch E; Held G; Poeschel V; Lesan V; Bittenbring JT; Thurner L; Pfreundschuh M; Christofyllakis K; Truemper L; Loeffler M; Schmitz N; Hoth M; Hallek M; Fischer K; Stilgenbauer S; Bewarder M; Rixecker TM
Lancet Haematol; 2022 Feb; 9(2):e133-e142. PubMed ID: 35114151
[TBL] [Abstract] [Full Text] [Related]
2. Intensified chemo-immunotherapy with or without stem cell transplantation in newly diagnosed patients with peripheral T-cell lymphoma.
Corradini P; Vitolo U; Rambaldi A; Miceli R; Patriarca F; Gallamini A; Olivieri A; Benedetti F; Todeschini G; Rossi G; Salvi F; Bruno B; Baldini L; Ferreri A; Patti C; Tarella C; Pileri S; Dodero A
Leukemia; 2014 Sep; 28(9):1885-91. PubMed ID: 24662801
[TBL] [Abstract] [Full Text] [Related]
3. Prognostic factors of Chinese patients with T/NK-cell lymphoma: a single institution study of 170 patients.
Xu PP; Wang Y; Shen Y; Wang L; Shen ZX; Zhao WL
Med Oncol; 2012 Sep; 29(3):2176-82. PubMed ID: 21710236
[TBL] [Abstract] [Full Text] [Related]
4. [Chronic lymphocytic leukemia in Subsaharian Africa: clinical outcome experience of Côte d'Ivoire].
Koffi KG; Nanho DC; Tolo A; N'Dathz E; Kouakou B; Meite N; Ayemou R; Sanogo I
Bull Cancer; 2009 Sep; 96(9):901-6. PubMed ID: 19696007
[TBL] [Abstract] [Full Text] [Related]
5. The expression of 16 genes related to the cell of origin and immune response predicts survival in elderly patients with diffuse large B-cell lymphoma treated with chop and rituximab.
Jais JP; Haioun C; Molina TJ; Rickman DS; de Reynies A; Berger F; Gisselbrecht C; Brière J; Reyes F; Gaulard P; Feugier P; Labouyrie E; Tilly H; Bastard C; Coiffier B; Salles G; Leroy K;
Leukemia; 2008 Oct; 22(10):1917-24. PubMed ID: 18615101
[TBL] [Abstract] [Full Text] [Related]
6. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline.
Smith TJ; Khatcheressian J; Lyman GH; Ozer H; Armitage JO; Balducci L; Bennett CL; Cantor SB; Crawford J; Cross SJ; Demetri G; Desch CE; Pizzo PA; Schiffer CA; Schwartzberg L; Somerfield MR; Somlo G; Wade JC; Wade JL; Winn RJ; Wozniak AJ; Wolff AC
J Clin Oncol; 2006 Jul; 24(19):3187-205. PubMed ID: 16682719
[TBL] [Abstract] [Full Text] [Related]
7. What is CD4+CD56+ malignancy and how should it be treated?
Reimer P; Rüdiger T; Kraemer D; Kunzmann V; Weissinger F; Zettl A; Konrad Müller-Hermelink H; Wilhelm M
Bone Marrow Transplant; 2003 Oct; 32(7):637-46. PubMed ID: 13130309
[TBL] [Abstract] [Full Text] [Related]
8. Mantle cell lymphoma: therapeutic strategies are different from CLL.
Hiddemann W; Dreyling M
Curr Treat Options Oncol; 2003 Jun; 4(3):219-26. PubMed ID: 12718799
[TBL] [Abstract] [Full Text] [Related]
9. Detection of minimal residual disease in B chronic lymphocytic leukemia (CLL).
Magnac C; Sutton L; Cazin B; Laurent C; Binet JL; Merle-Béral H; Dighiero G; Maloum K
Hematol Cell Ther; 1999 Feb; 41(1):13-8. PubMed ID: 10193641
[TBL] [Abstract] [Full Text] [Related]
